Virios Therapeutics (VIRI) Competitors $4.89 -0.01 (-0.14%) As of 09/12/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock VIRI vs. AUTL, DMAC, MBX, BNTC, IMAB, CTMX, RCKT, ABEO, ALDX, and UPXIShould you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include Autolus Therapeutics (AUTL), DiaMedica Therapeutics (DMAC), MBX Biosciences (MBX), Benitec Biopharma (BNTC), I-Mab (IMAB), CytomX Therapeutics (CTMX), Rocket Pharmaceuticals (RCKT), Abeona Therapeutics (ABEO), Aldeyra Therapeutics (ALDX), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry. Virios Therapeutics vs. Its Competitors Autolus Therapeutics DiaMedica Therapeutics MBX Biosciences Benitec Biopharma I-Mab CytomX Therapeutics Rocket Pharmaceuticals Abeona Therapeutics Aldeyra Therapeutics Upexi Virios Therapeutics (NASDAQ:VIRI) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends. Is VIRI or AUTL more profitable? Autolus Therapeutics' return on equity of -56.18% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% Autolus Therapeutics N/A -56.18%-29.61% Do analysts prefer VIRI or AUTL? Virios Therapeutics currently has a consensus target price of $5.00, suggesting a potential upside of 2.25%. Autolus Therapeutics has a consensus target price of $9.12, suggesting a potential upside of 590.91%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, VIRI or AUTL? Virios Therapeutics has higher earnings, but lower revenue than Autolus Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-18.11Autolus Therapeutics$10.12M34.71-$220.66M-$0.84-1.57 Does the media favor VIRI or AUTL? In the previous week, Autolus Therapeutics had 5 more articles in the media than Virios Therapeutics. MarketBeat recorded 5 mentions for Autolus Therapeutics and 0 mentions for Virios Therapeutics. Autolus Therapeutics' average media sentiment score of 1.12 beat Virios Therapeutics' score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Virios Therapeutics Neutral Autolus Therapeutics Positive Which has more volatility & risk, VIRI or AUTL? Virios Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Do insiders and institutionals hold more shares of VIRI or AUTL? 9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryAutolus Therapeutics beats Virios Therapeutics on 12 of the 14 factors compared between the two stocks. Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRI vs. The Competition Export to ExcelMetricVirios TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$94.17M$833.26M$5.75B$10.24BDividend YieldN/A4.84%5.69%4.60%P/E Ratio-18.111.1874.9326.41Price / SalesN/A121.58452.3586.56Price / CashN/A19.5625.8129.91Price / Book24.456.6613.256.28Net Income-$5.30M-$4.13M$3.29B$270.38M7 Day Performance-0.20%2.15%0.47%2.70%1 Month Performance-0.61%8.15%4.60%5.99%1 Year Performance2,408.98%26.42%73.42%25.94% Virios Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRIVirios TherapeuticsN/A$4.89-0.1%$5.00+2.2%+2,409.0%$94.17MN/A-18.115AUTLAutolus Therapeutics3.9053 of 5 stars$1.40-2.4%$9.12+553.8%-66.2%$371.27M$10.12M-1.66330Positive NewsShort Interest ↓DMACDiaMedica Therapeutics2.0351 of 5 stars$7.12-0.6%$12.33+73.2%+57.6%$367.26MN/A-10.3020MBXMBX Biosciences0.13 of 5 stars$10.91+0.1%N/AN/A$366.51MN/A-2.40N/ANews CoverageAnalyst UpgradeBNTCBenitec Biopharma1.6695 of 5 stars$13.75-0.7%$26.00+89.1%+69.9%$360.94M$80K-9.1120Positive NewsIMABI-Mab2.6342 of 5 stars$4.31+0.9%$7.00+62.4%+285.8%$352.20M$3.89M0.00380Gap DownCTMXCytomX Therapeutics4.1471 of 5 stars$2.09-4.4%$5.75+175.8%+62.6%$347.14M$138.10M3.76170News CoveragePositive NewsRCKTRocket Pharmaceuticals4.7908 of 5 stars$3.20-2.0%$16.73+423.7%-83.9%$344.74MN/A-1.27240Positive NewsShort Interest ↑ABEOAbeona Therapeutics4.1136 of 5 stars$6.69-0.2%$19.50+191.7%+15.2%$344.24M$3.50M9.5990Positive NewsALDXAldeyra Therapeutics2.3305 of 5 stars$5.65-0.9%$9.50+68.1%-10.6%$337.81MN/A-6.6410Positive NewsUPXIUpexi3.0411 of 5 stars$5.66-0.1%$15.50+174.0%+73.7%$337.15M$26M0.00130Short Interest ↓ Related Companies and Tools Related Companies Autolus Therapeutics Alternatives DiaMedica Therapeutics Alternatives MBX Biosciences Alternatives Benitec Biopharma Alternatives I-Mab Alternatives CytomX Therapeutics Alternatives Rocket Pharmaceuticals Alternatives Abeona Therapeutics Alternatives Aldeyra Therapeutics Alternatives Upexi Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRI) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIRI Stock Alerts